Morphic Appoints Dr. Simon Cooper as Chief Medical Officer [Yahoo! Finance]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Yahoo! Finance
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. “Simon brings clinical development expertise stemming from leadership roles across the entire spectrum of clinical development from first-in-human studies through FDA submissions and approvals of highly successful therapeutics. Of particular relevance to Morphic as we advance MORF-057, is Simon's experience in the development and appro
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.MarketBeat
- Morphic appoints Simon Cooper as CMO [Seeking Alpha]Seeking Alpha
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $100.00 price target on the stock.MarketBeat
- Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes [Yahoo! Finance]Yahoo! Finance
KROS
Earnings
- 2/28/24 - Beat
KROS
Sec Filings
- 4/17/24 - Form ARS
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- KROS's page on the SEC website